Anti-CD40 therapy extends renal allograft survival in rhesus macaques1
Thomas C. Pearson(Emory Healthcare), Christian P. Larsen(Emory University Hospital), Joel Trambley(Emory University), Robert A. Bray(Emory University), Randall Hennigar(Emory University), Elizabeth Strobert(Emory University), Anthony W. Siadak(Seagen (United States)), Alejandro Aruffo(University of Washington Medical Center), Kris Odom(Emory University), Angello Lin(Emory University), Shannon Cowan(Emory University), Daniel C. Anderson(Emory University), Diane Hollenbaugh(Neoleukin Therapeutics (United States))
Cited by 160
Related Papers
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome
|Cell|1993|824
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation
|Transplantation|2012|777
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714